Eli Lilly and Company (NYSE:LLY) Posts Earnings Results, Beats Estimates By $0.06 EPS

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Wednesday. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06, FiscalAI reports. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue was up 42.6% on a year-over-year basis. During the same quarter last year, the company posted $5.32 earnings per share. Eli Lilly and Company updated its FY 2026 guidance to 33.500-35.000 EPS.

Here are the key takeaways from Eli Lilly and Company’s conference call:

• Financial strength: Lilly reported 2025 revenue of $65.2 billion (+45%) and EPS of $24.21 (+86%), and guided 2026 revenue to $80–83 billion with EPS of $33.50–35.00, signaling material top‑ and bottom‑line growth expectations.
• Orforglipron and oral expansion: Lilly submitted Orforglipron for obesity in the U.S. and 40+ countries, expects a U.S. launch in Q2 2026, and is positioning oral GLP‑1s as market‑expanding rather than purely cannibalistic.
• Retatrutide efficacy: Phase 3 TRIUMPH‑4 showed retatrutide 12 mg produced an average 29% weight loss at 68 weeks and large pain/function improvements in knee osteoarthritis, supporting potential use for patients with severe obesity and comorbidities.
• Access and pricing tradeoffs: Lilly agreed with the U.S. government to offer obesity medicines to Medicare/Medicaid patients at a $50/month out‑of‑pocket copay (effective by July 1, 2026), while warning that price concessions will drag 2026 growth in the low‑ to mid‑teens but should be offset by volume expansion over time.
• R&D and pipeline momentum: The company highlighted broad late‑stage progress—including full FDA approval and label expansion for pirtobrutinib and ~80% PFS risk reduction in a frontline CLL study—alongside 36 active Phase 3 programs and multiple new trial starts and BD deals.

Eli Lilly and Company Trading Down 6.9%

Shares of LLY traded down $76.42 on Thursday, hitting $1,030.70. 2,907,601 shares of the stock traded hands, compared to its average volume of 3,196,579. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm has a market capitalization of $974.40 billion, a P/E ratio of 50.39, a P/E/G ratio of 0.76 and a beta of 0.39. The stock’s 50 day moving average is $1,054.31 and its two-hundred day moving average is $895.30. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 29.35%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and strong 2026 outlook — Lilly topped revenue and EPS estimates on surging sales of Mounjaro and Zepbound and gave upbeat 2026 guidance that underpinned the recent rally. Eli Lilly Beats Q4 Estimates But Shares Slide
• Positive Sentiment: Analysts remain constructive — at least one analyst kept an outperform rating and raised the price target (to $1,300), signaling continued confidence in Lilly’s multi‑year growth runway. Eli Lilly Beats Q4 Estimates But Shares Slide
• Positive Sentiment: Execution and capacity expansion support volume growth — MarketBeat’s sector coverage highlights Lilly’s manufacturing build‑out and vial strategy that helped offset U.S. pricing pressure by driving a big volume increase. The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles
• Neutral Sentiment: Ongoing capital investment — Lilly announced sizable new manufacturing spending (e.g., a $3.5B Pennsylvania facility), which supports longer‑term supply but is near‑term capex intensive. Eli Lilly to Invest Over $3.5 Billion in New Manufacturing Facility
• Neutral Sentiment: Pipeline and M&A activity diversify long‑term upside — deals (e.g., hearing‑loss and other collaborations) broaden optionality beyond GLP‑1s but will take time to materialize. Eli Lilly Is Getting Into the Hearing Loss Market
• Negative Sentiment: New low‑price competitor copy accelerates pricing fears — telehealth firm Hims & Hers announced a $49 copy of Wegovy, stoking concerns that cheaper entrants and pricing pressure could erode margins and force faster price competition across the GLP‑1 category. That news is a near‑term catalyst for the pullback. Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Profit‑taking and volatility after a huge run — after the stock surged on the beat and guidance (reclaiming ~$1T market cap), some investors are locking gains; analysts and outlets warn a pullback is possible given the stock’s run and valuation sensitivity to GLP‑1 pricing assumptions. Why Eli Lilly Stock Just Dropped

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors have recently added to or reduced their stakes in LLY. Brighton Jones LLC boosted its position in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC lifted its position in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Schnieders Capital Management LLC. boosted its holdings in Eli Lilly and Company by 16.7% in the 2nd quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock worth $6,231,000 after acquiring an additional 1,141 shares during the period. Flow Traders U.S. LLC acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $356,000. Finally, Nebula Research & Development LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Jefferies Financial Group boosted their target price on Eli Lilly and Company from $976.00 to $1,300.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Monday. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 31st. Finally, National Bankshares set a $1,286.00 price objective on shares of Eli Lilly and Company in a research note on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,185.17.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.